TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Waldencast ( (WALD) ).
On November 24, 2025, Waldencast plc announced its Q2 2025 financial results and provided a Q3 2025 trading update. The company reported a 5.6% year-over-year net revenue growth in Q2, driven by strong performance in the U.S. for Milk Makeup and international growth for Obagi Medical. However, Milk Makeup faced challenges in international markets during Q3. Waldencast advanced strategic initiatives, including acquiring Novaestiq and selling the Obagi Japan trademark, to strengthen its balance sheet and focus on long-term growth. The company updated its full-year guidance to reflect these trends and investments.
The most recent analyst rating on (WALD) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Waldencast stock, see the WALD Stock Forecast page.
Spark’s Take on WALD Stock
According to Spark, TipRanks’ AI Analyst, WALD is a Neutral.
Waldencast Acquisition’s overall stock score reflects strong technical momentum and a positive outlook from recent earnings calls. However, financial performance is hindered by ongoing profitability challenges and cash flow issues, while valuation metrics remain unattractive due to negative earnings.
To see Spark’s full report on WALD stock, click here.
More about Waldencast
Waldencast plc is a global multi-brand beauty and wellness platform, focusing on beauty and skincare products. The company operates brands such as Obagi Medical and Milk Makeup, with a market focus on both U.S. and international channels.
Average Trading Volume: 127,939
Technical Sentiment Signal: Sell
Current Market Cap: $378M
For an in-depth examination of WALD stock, go to TipRanks’ Overview page.